Background: Accumulating evidence suggests that coronavirus disease 2019 (COVID-19) is
associated with hypercoagulative status, particularly for critically ill patients in the intensive …

Patients with COVID-19 present with a wide variety of clinical manifestations.
Thromboembolic events constitute a significant cause of morbidity and mortality in patients …

Immunothrombosis—immune-mediated activation of coagulation—is protective against
pathogens, but excessive immunothrombosis can result in pathological thrombosis and …

Several independent lines of evidence suggest that megakaryocytes are dysfunctional in
severe COVID-19. Herein, we characterized peripheral circulating megakaryocytes in a …

Venous disease is a term that broadly covers both venous thromboembolic disease and
chronic venous disease. The basic pathophysiology of venous thromboembolism and …

Coronavirus disease 2019 (COVID-19) is a highly prothrombotic viral infection that primarily
manifests as an acute respiratory syndrome. However, critically ill COVID-19 patients will …

The infection with the SARS-CoV-2 virus is associated with numerous systemic
involvements. Besides the severe respiratory injuries and cardiovascular complications, it …

Abstract On March 11, 2020, the World Health Organization declared Coronavirus Disease
2019 (COVID-19) a pandemic. Till now, it affected 452.4 million (Spain, 11.18 million) …

Severe COVID-19 patients frequently present thrombotic complications which commonly
lead to multiorgan failure and increase the risk of death. Severe SARS-CoV-2 infection …

There is strong evidence that COVID-19 pathophysiology is mainly driven by a
spatiotemporal immune deregulation. Both its phenotypic heterogeneity, spanning from …